Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Nsclc Patients'
Nsclc Patients published presentations and documents on DocSlides.
Raising the Bar in the Management of Advanced/Metastatic NSCLC
by debby-jeon
Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...
SW GLH services for NSCLC – An update
by everly
Professor Rachel Butler. The genomic complexity of...
NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti
by sawyer742
Intervista a Federico . Cappuzzo. Background:. Pr...
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
David R.
by alida-meadow
Gandara. , MD. University of California, Davis . ...
NSCLC with high PD-L1 expression on tumor cells or tumor-in
by test
Intervista a Federico . Cappuzzo. Background:. P...
Comparision
by jane-oiler
of the expression of . 17-beta-hydroxysteroid . ...
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
by pasty-toler
This program will include a discussion of off-lab...
The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature
by stefany-barnette
The Cancer genome atlas (TCGA) and the search for...
NSCLC: Epidemiology and disease characteristics
by scarlett
NSCLC, non-small cell lung cancer.. Lung cancer in...
Multidisciplinary approach to lung cancer
by elena
Kamil Konopka. Department of Oncology, University ...
Slides last updated:
by calandra-battersby
October 2013. There are two main types of lung . ...
Lung malignancy
by tawny-fly
Dr. Rachel Cary, FY1 Warwick Hospital. Learning ...
Slides last updated:
by stefany-barnette
October 2013 . Ferlay . J, Shin HR, Bray F, Forma...
L’algoritmo terapeutico
by calandra-battersby
attraverso . i . c. asi clinici. Giuseppe . Valma...
Estimated costs of managing treatment-related adverse
by lindy-dunigan
eventsof. . nivolumab. and . docetaxel. in the...
Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%
by olivia-moreira
Low TPS High TPS TPS = PD-L1 tumor proportion sco...
ASCO 2019 NSCLC - PARP & Chemotherapy
by mitsue-stanley
ASCO 2019 NSCLC - PARP & Chemotherapy REF Stu...
OMICS International welcomes submissions that are original and technically so as to serve both th
by lois-ondreau
OMICS Journals are poised in excellence by publi...
Module 13: Targeted Treatment
by disclaimercanon
of Lung Cancer . Wendi S Lee, MSN, RN, NP-C. Anne ...
Presented at the European Society for Medical Oncology 2019 Barcelona
by lucy
– 1 October, 2019 ● GSK 3377794 activate and i...
NSCLC: Staging and TNM classification
by molly
NSCLC, non-small cell lung cancer; TNM. , tumour, ...
mRNA anticancer Vaccines
by byrne
breakthrough. . approach. in . cancer. . treatm...
ALL, Acute lymphoblastic leukemia;
by HappyHippo
BCMA, B-cell maturation antigen; DLBCL, diffuse la...
Jchem applications in Medchem
by StarsAndStripes
Prediction. . and. . Data Sorting. Zhengtao. Li...
cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi
by adia
RecommendationLoE, GoRScreening with LDCT (low-dos...
NonSmallCellLungCancerVersion32022DavidSEttingerMDDouglasEWoodM
by cecilia
NCCNCATEGORIESOFEVIDENCEANDCONSENSUSCategory1:Base...
AdjuvantTherapyforStageIandIINonSmallCellLungCancerEvanCNaylorPatie
by susan2
DisclosureStatement:Theauthorhasnothingtodisclose....
Checkpoint inhibitors for
by paisley
NSCLC. An update. Solange Peters, MD-PhD. Oncology...
Updates in the systemic treatment for lung
by madeline
cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....
FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY
by pamela
Case study 9. Provided by . Dr Qamar Ghafoor, Clin...
CLINICAL EXPERIENCE OF NSCLC in RSDM
by sophia
Ana Rima. PENDAHULUAN. 2. Kanker Paru. P. enyebab ...
Istituto Toscano Tumori –Livorno, Italy
by payton
Federico . Cappuzzo. Istituto Toscano Tumori. Ospe...
Roberto Bianco Laboratori di Terapia Molecolare dei Tumori
by finley
Università . di Napoli “Federico II”. Innovat...
Striving for Consensus on the
by samantha
Optimal Management of Metastatic . Non-Small Cell ...
Load More...